Michael Gilman (Credit: Obsidian)

Roche makes a plat­form play, bet­ting $190M in cash on Ar­rakis’ long-haul plans to drug RNA

Every biotech start­up sets out at its own idea of a de­lib­er­ate pace. And they of­ten fall in­to 2 sep­a­rate styles.

There are the sprint­ers who leap straight in­to a slate of deals, look­ing to align them­selves with the kind of blue chip part­ners that help val­i­date their place in the de­vel­op­ment pipeline.

And then there are the marathon, long-haul biotechs like Ar­rakis, which take a more mea­sured ap­proach.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.